Hoelzer K L, Harrison B R, Luedke D W, Mahanta B
Cancer Treat Rep. 1986 Oct;70(10):1211-2.
Dacarbazine has shown the most consistent activity of any single chemotherapeutic agent in patients with metastatic melanoma. While the overall rate is 21%, responses fall to less than 10% when hepatic metastases are present. We report a patient with malignant melanoma metastatic to the liver in whom an apparent dose-response relationship to dacarbazine was demonstrated. His liver metastases responded to hepatic artery infusion, progressed with systemic iv therapy, and responded upon reinstitution of hepatic artery infusion.
达卡巴嗪在转移性黑色素瘤患者中展现出比任何单一化疗药物都更为稳定的活性。虽然总体有效率为21%，但当存在肝转移时，有效率会降至10%以下。我们报告了一名发生肝转移的恶性黑色素瘤患者，该患者显示出对达卡巴嗪明显的剂量反应关系。其肝转移灶对肝动脉灌注有反应，在全身静脉治疗时进展，而在重新进行肝动脉灌注时又有反应。
